Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Investors Are Watching Dean Foods, Regeneron Pharmaceuticals, Halliburton, and More

QUALCOMM, Inc. (NASDAQ:QCOM) is in the spotlight today after Tim Long of BMO Capital raised his price target to $70 per share from the previous $53 and upgraded the stock to ‘Market Perform’ from ‘Underperform’. Although Long thinks Qualcomm’s core fundamentals will remain challenged, he expects the stock to be range-bound due to the company’s recent deal to buy NXP. A total of 48 funds from our database were long QUALCOMM, Inc. (NASDAQ:QCOM) at the end of June, down by 11 funds from the previous quarter.

Follow Qualcomm Inc (NASDAQ:QCOM)
Trade (NASDAQ:QCOM) Now!

Traders are watching the price action surrounding Halliburton Company (NYSE:HAL) after General Electric Company (NYSE:GE) announced that it was seeking a potential partnership with Baker Hughes Incorporated (NYSE:BHI). Although GE has said it isn’t interested in buying Baker Hughes, a partnership would strengthen Baker and could potentially take some market share away from Halliburton. Given that prospect, it’s not surprising that Halliburton is down 0.9% at a time when its peers such as Schlumberger Limited. (NYSE:SLB) are in the green. At the end of June, 62 funds followed by our team owned shares of Halliburton Company (NYSE:HAL), up by eight funds from the previous quarter.

Follow Halliburton Co (NYSE:HAL)
Trade (NYSE:HAL) Now!

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares are off by 4% after the company disclosed in a regulatory filing that its collaborator, Sanofi SA (ADR) (NYSE:SNY), was notified of manufacturing deficiencies raised by the FDA in a Sanofi facility that conducts “fill and finish” activities for certain products, including sarilumab, an antibody to the interleukin-6 receptor being developed by Regeneron in collaboration with Sanofi. Due to the FDA notification, it is unclear how the situation will impact the timing of the potential approval of sarilumab by the FDA. The expected action date for the sarilumab BLA was/is October 30, 2016. A total of 32 funds tracked by Insider Monkey amassed around 2% of Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s outstanding stock on June 30.

Follow Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
Trade (NASDAQ:REGN) Now!

Disclosure: none

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.